The company is searching for a Chief Medical Officer to ensure its continued success, and to assist the company in transforming its 3D Telomere Technology into a disruptive platform of diagnostic/prognostic tests that will become commercially attractive to clinically laboratory partners and diagnostic companies. 3DS is at the late stage of completing its validation work on the company’s proof of principle Hodgkin’s lymphoma test and it expects to identify a commercial partner in 2017. In addition, the company intends to evaluate additional clinical development opportunities for its technology in prostate cancer, multiple myeloma, lung cancer, Alzheimer’s disease and breast cancer to name a few. The CMO will be based in Toronto, Canada, and report to the CEO, also in Toronto. She/he will have responsibility for the clinical strategy, implementation of the clinical development and operations plan, as well as oversight of the daily operation of test/assay development projects. She/he will collaborate with key internal stakeholders such as the CBO, CFO, VP Clinical, Director Clinical Operations and external stakeholders including CROs, key opinion leaders, investors, analysts and the company’s Clinical and Scientific Advisory Board (CSAB), including the CSAB Chair and co-founder of 3DS. The Chief Medical Officer will join the company’s senior leadership team.